Skip to main content
. 2021 Dec 3;37(12):110126. doi: 10.1016/j.celrep.2021.110126

Figure 3.

Figure 3

Blood IFP35 reflected the turnover of individuals with COVID-19

(A and B) Serum IFP35 (A) and IL-6 (B) in 8 severely ill individuals with COVID-19 before and after treatment. Significance was calculated by two-tailed Wilcoxon matched-pairs signed rank test (p < 0.05, ∗∗p < 0.01).

(C) Chest computed tomography (CT) in a severely ill individual with COVID-19 before and after treatment. The bilateral, multiple, patchy, ground-glass opacities before treatment are indicated by red arrows and were located in the same position after treatment when the lesions were improved.

(D and E) IFP35 (D) and IL-6 (E) in the sera of individuals in group 2. Data from 11 deceased individuals and 26 improved individuals are shown as orange dots and blue dots, respectively.